Baneocin, powder 250 me/g+5000 me/g 10 g

Pharmacodynamics

Baneocin is a combined antibacterial drug for topical use.

Baneocin contains two bactericidal antibiotics: neomycin and bacitracin.

Bacitracin is a polypeptide antibiotic that inhibits the synthesis of the bacterial cell membrane.

Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis.

Bacitracin is active against Gram-positive microorganisms such as beta-hemolytic streptococci, staphylococci, and some Gram-negative pathogens. Resistance to bacitracin is extremely rare.

Neomycin is effective against Gram-positive and Gram-negative microorganisms.

The combination of the two agents has achieved a broad spectrum of the drug and synergistic action against a number of microorganisms, such as Staphylococcus aureus.

Pharmacokinetics

The active ingredients are generally not absorbed (even by damaged skin), but high concentrations are present in the skin.

Baneocin is well tolerated. Tissue tolerance is rated as excellent, no inactivation by biological products, blood and tissue components has been noted. If the drug is applied to large areas of skin lesions, the possibility of absorption of the drug and its consequences must be taken into account.

Indications

Baneocin is indicated for use in infections caused by microorganisms sensitive to neomycin and/or bacitracin.

bacterial skin infections of limited prevalence, for example with weeping contagious impetigo, infected trophic ulcers of the lower extremities, infected eczema, bacterial diaper dermatitis, bacterial complications (Herpes simplex and Herpes zoster, or varicella vesicles);
prevention of umbilical infection in newborns;
prevention of infection after surgical (dermatological) procedures – Baneocin powder can be used for additional treatment in the postoperative period (after excision, cauterization, episiotomy, for the treatment of cracks in the skin, weeping wounds and sutures).

Pharmacological effect

Pharmacodynamics

Baneocin is a combined antibacterial drug intended for topical use.

Baneocin contains two bactericidal antibiotics: neomycin and bacitracin.

Bacitracin is a polypeptide antibiotic that inhibits the synthesis of bacterial cell walls.

Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis.

Bacitracin is active against gram-positive microorganisms such as beta-hemolytic streptococci, staphylococci, and some gram-negative pathogens. Resistance to bacitracin is extremely rare.

Neomycin is effective against gram-positive and gram-negative microorganisms.

Thanks to the use of a combination of these two substances, a wide spectrum of action of the drug and synergistic action against a number of microorganisms, such as staphylococci, are achieved.

Pharmacokinetics

The active substances, as a rule, are not absorbed (even by damaged skin), however, they are present in high concentrations in the skin.

Baneocin is well tolerated. Tissue tolerance is assessed as excellent; inactivation by biological products, blood and tissue components is not observed. If the drug is applied to large areas of skin lesions, the possibility of absorption of the drug and its consequences should be taken into account.

Special instructions

When used in doses significantly higher than recommended, due to the possible absorption of the drug Baneocin, special attention should be paid to symptoms indicating nephro- and/or ototoxic reactions.

Since the risk of toxic effects increases with decreased liver and/or kidney function, blood and urine tests together with audiometric testing should be performed in patients with hepatic and/or renal insufficiency before and during therapy with Baneocin.

If absorption of Baneocin occurs, attention should be paid to potential blockade of neuromuscular conduction, especially in patients with acidosis, concomitant myasthenia gravis or other neuromuscular diseases.

During long-term treatment, attention should be paid to the possible growth of resistant microorganisms. In such situations, appropriate treatment should be prescribed.

In case of using the drug in children, patients with impaired liver and kidney function, as well as with a large area of ​​​​the treated surface, long-term use and deep skin lesions, it is recommended to first consult a doctor.

For patients who develop an allergy or superinfection, the drug should be discontinued.

Active ingredient

Bacitracin, Neomycin

Composition

Active ingredients:

zinc-bacitracin 250 IU,

neomycin sulfate 5000 IU (5 mg);

Excipients:

sterilized powder base (corn starch containing no more than 2% magnesium oxide)

Pregnancy

The use of Baneocin during pregnancy and breastfeeding is possible only after consultation with a doctor if the expected benefit to the mother outweighs the potential risk to the fetus and infant.

Contraindications

Hypersensitivity to bacitracin and/or neomycin, or to other aminoglycoside antibiotics;
extensive skin lesions, since absorption of the drug can cause an ototoxic effect accompanied by hearing loss;
severe disturbances in excretory function due to heart or renal failure and existing lesions of the vestibular and cochlear systems in cases where absorption of the drug is possible.
Do not use the powder for eye treatment!

With caution:

if absorption is possible (extensive damage to the integrity of the skin), it is necessary to monitor the possible appearance of signs of neuromuscular blockade, especially in patients with acidosis, myasthenia gravis or other neuromuscular diseases. If neuromuscular blockade develops, calcium supplements or neostigmine are indicated;
with long-term use of the drug, it is necessary to monitor the possible excessive growth of resistant organisms. If this occurs, appropriate treatment should be prescribed;
Treatment with Baneocin in patients who develop allergic reactions or superinfection should be discontinued.

Side Effects

According to the World Health Organization (WHO), adverse effects are classified according to their frequency as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10000 to <1/1000), very rare (<1/10000); frequency unknown - based on available data, it was not possible to determine the frequency of occurrence. Baneocin® is usually well tolerated when used externally.

Immune system disorders

rarely: allergic reactions (if there is a history of allergic reactions to neomycin in 50% of cases, cross-allergy to other aminoglycosides may develop); frequency unknown: increased sensitivity to various substances, including neomycin (usually observed when used in the treatment of chronic dermatoses); in some cases, allergic reactions may appear as a lack of effect from the therapy.

Nervous system disorders

frequency unknown: vestibular nerve damage, neuromuscular blockade.

Hearing and labyrinth disorders

frequency unknown: ototoxicity.

Skin and subcutaneous tissue disorders

rarely: allergic reactions manifesting as contact dermatitis, allergic reaction to neomycin;

frequency unknown: allergic reactions in the form of redness and dryness of the skin, skin rashes and itching (with prolonged use).

Renal and urinary tract disorders

frequency unknown: nephrotoxicity.

If any of the side effects indicated in the instructions worsen, or any other side effects not listed in the instructions are noted, you should immediately inform your doctor.

Interaction

With systemic absorption of the active components of the drug, simultaneous use of cephalosporins or aminoglycoside antibiotics may increase the likelihood of nephrotoxic reactions.

Simultaneous use of diuretics such as ethacrynic acid or furosemide with Baneocin® powder can provoke oto- and nephrotoxic effects.

Absorption of the active components of the drug Baneocin® may enhance the effects of blockade of neuromuscular conduction in patients receiving narcotic substances, anesthetics and/or muscle relaxants.

Overdose

When used in doses significantly higher than recommended, due to the possible absorption of the active components of Baneocin® powder, special attention should be paid to symptoms indicating nephro- and/or ototoxic reactions.

Storage conditions

In a place protected from light and moisture, at a temperature not exceeding 25 °C

Shelf life

2 years.

Do not use after the expiration date stated on the package.

Manufacturer

Pharmaceuticals Fabrik Montavit GmbH, Austria